Question · asked by 1 review
Sumatriptan 50 mg or 85 mg plus naproxen 500 mg vs placebo: Serious AE (all levels of baseline pain)
- Population
- adults with migraine headache ‐ moderate or severe and mild baseline pain
- Intervention
- Sumatriptan 50 mg or 85 mg plus naproxen 500 mg
- Comparison
- placebo
- Outcome
- Serious AE (all levels of baseline pain)
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Sumatriptan 50 mg or 85 mg plus naproxen 500 mg vs placebo Serious AE (all levels of baseline pain) · adults with migraine headache ‐ moderate or severe and mild baseline pain The review found no eligible studies for this question. Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults (2016) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults 2016 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.